Strategic report Corporate governance Financial statements Financial statements Notes to the Company financial statements continued For the year ended 31 December 2016 47.
Financial assets The details of Investment in subsidiaries are mentioned in note 41.
Cash and cash equivalents As at 31 December The following table provides the movement of the investments in subsidiaries: 2016 2015 $m $m 2016 2015 $m $m Cash at banks and on hand Beginning balance 1,888 2,033 Time deposits 5 324 Additions Transfers from to subsidiaries 1,908 Money market deposits 27 39 Transfer from Goodwill 43 32 363 Reduction in investment 650 These comprise cash held by the Company and short-term bank deposits with an original maturity of three months or less.
The carrying Reduction in paid up capital 10 145 amount of these assets approximates to their fair value.
Financial liabilities This category relates to an intragroup restructuring following the acquisition of West-Ward Columbus.
In 2016, the capital of Hikma Finance Luxembourg SARL was reduced by $10 million, in previous period a reduction of $108 million in Hikma Finance Luxembourg SARL, in addition the capital contribution of $37 million to Eurohealth International SARL was reversed as the conditions of the contribution Other payables were not satisfied.
Part of this capital reduction is related to the transfer of intangibles from sister companies.
The Directors consider that the carrying amount of other payables approximates to their fair value.
Due from subsidiaries and sister companies 52.
Due to subsidiaries and sister companies Non-current assets 2016 2015 Non-current liabilities $m $m 2016 2015 West-Ward Pharmaceuticals Corp. 8 56 $m $m Hikma Italia S. P. A 4 5 Hikma Maple Limited 44 44 Hikma Investment LLC 1 1 Hikma MENA Holdings 7 7 West-Ward Pharmaceuticals International Limited 488 Eurohealth International SARL 10 Eurohealth International SARL 47 55 45 507 115 Current liabilities Increase in respect of dividends in specie as part of an intragroup restructuring following the acquisition of West-Ward Columbus.
2016 2015 $m $m Current assets Hikma Investment LLC 5 5 2016 2015 West-Ward USA 31 $m $m Hikma Farmaceutica S. A 2 Hikma Pharmaceuticals - Jordan 3 Thymoorgan GmbH 1 3 Hikma UK Limited 62 88 West-Ward Pharmaceuticals International Limited 24 Hikma MENA Holdings 7 7 Hikma Pharma Limited - Jersey 2 West-Ward Pharmaceutical Corp. 33 Others 1 Hikma Pharma SAE 2 2 32 42 Eurohealth International SARL 17 Hikma finance Luxembourg SARL 3 Hikma Emerging Markets and Asia Pacific FZ-LLC Dubai 1 108 117 49.
Other current assets 2016 2015 $m $m Price adjustment receivable note 43 34 Investment designated at fair value 20 20 Co-development and earnout Receivable 3 2 Others 2 59 22 Investment designated at fair value: represents the agreement the Group entered in 2015 with an asset management firm to manage a $20 million portfolio of underlying debt instruments.
The asset is measured at fair value and classed as level 1 as it uses quoted prices in active markets.
Annual Report 2016 205 196 Hikma Pharmaceuticals plc Annual Report 2016 197
